Home » VICAL'S EBOLA DRUG SHOWS PROMISE
VICAL'S EBOLA DRUG SHOWS PROMISE
In a Phase I trial, Vical's Ebola vaccine candidate, administered using the company's proprietary DNA-delivery technology, was shown to be safe and well-tolerated. The candidate was also shown to produce both antibody and T-cell Ebola-specific responses in all healthy volunteers who received the full three doses of vaccine.
The randomized, placebo-controlled, dose-escalation study, the first human trial for any Ebola vaccine, was sponsored by the National Institutes of Health (NIH), and conducted at the NIH Clinical Center.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May